Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell P Levesque

Showing results (141-150 of 203) with videos related to

Pageof 21
Sort By:
Cancer Research|October 14, 2021
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma ProgressionAnnalisa Saltari, Andreas Dzung, Marika Quadri, et al.
Molecular Systems Biology|August 21, 2023
Robust dimethyl-based multiplex-DIA doubles single-cell proteome depth via a reference channelMarvin Thielert, Ericka Cm Itang, Constantin Ammar, et al.
Frontiers in Cell and Developmental Biology|May 16, 2022
An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin BiopsiesBlaž Burja, Dominique Paul, Aizhan Tastanova, et al.
Cancer Cell|July 17, 2018
EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma FormationDaniel Zingg, Julien Debbache, Rodrigo Peña-Hernández, et al.
Cell Stem Cell|April 6, 2019
Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma FormationSandra Varum, Arianna Baggiolini, Luis Zurkirchen, et al.
Nature Cancer|August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanomaFlorentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
Nature Communications|January 23, 2015
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressorsDaniel Zingg, Julien Debbache, Simon M Schaefer, et al.
Cancer Research|September 20, 2023
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced MelanomaLorenza P Ferretti, Flurina Böhi, Deena M Leslie Pedrioli, et al.
Plos Genetics|January 29, 2015
Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanomaOlga Shakhova, Phil Cheng, Pravin J Mishra, et al.
The Journal of Experimental Medicine|November 4, 2025
Transcriptomics- and 3D imaging-based characterization of the lymphatic vasculature in human skinAline Bauer, Lito Zambounis, Ioannis Kritikos, et al.
Pageof 21

Showing results (141-150 of 203) with videos related to

Sort By:
Pageof 21
Cancer Research|October 14, 2021
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma ProgressionAnnalisa Saltari, Andreas Dzung, Marika Quadri, et al.
Molecular Systems Biology|August 21, 2023
Robust dimethyl-based multiplex-DIA doubles single-cell proteome depth via a reference channelMarvin Thielert, Ericka Cm Itang, Constantin Ammar, et al.
Frontiers in Cell and Developmental Biology|May 16, 2022
An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin BiopsiesBlaž Burja, Dominique Paul, Aizhan Tastanova, et al.
Cancer Cell|July 17, 2018
EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma FormationDaniel Zingg, Julien Debbache, Rodrigo Peña-Hernández, et al.
Cell Stem Cell|April 6, 2019
Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma FormationSandra Varum, Arianna Baggiolini, Luis Zurkirchen, et al.
Nature Cancer|August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanomaFlorentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
Nature Communications|January 23, 2015
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressorsDaniel Zingg, Julien Debbache, Simon M Schaefer, et al.
Cancer Research|September 20, 2023
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced MelanomaLorenza P Ferretti, Flurina Böhi, Deena M Leslie Pedrioli, et al.
Plos Genetics|January 29, 2015
Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanomaOlga Shakhova, Phil Cheng, Pravin J Mishra, et al.
The Journal of Experimental Medicine|November 4, 2025
Transcriptomics- and 3D imaging-based characterization of the lymphatic vasculature in human skinAline Bauer, Lito Zambounis, Ioannis Kritikos, et al.
Pageof 21